Smith, Gambrell & Russell represented Canadian company Urigen Holdings Inc. in which the shareholders are acquiring majority control of Valentis, Inc. Valentis develops heart-disease drugs while Urigen focuses on urological products.
The SGR team assembled for this transaction included Tim Elder, Dennis Doherty, Terry Schwartz and Emily Avant.
© 2010, Smith, Gambrell & Russell, LLP